B-Cell Exosome Screening for Immune Checkpoint Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint blockade therapies for cancer treatment face challenges with high toxicity and unpredictability in patient response, necessitating a need for biomarkers to predict toxicity and response effectively.
Innovation Solution
Identifying patient populations for immune checkpoint blockade therapy by measuring B-cell exosomes in biological samples, using methods such as immunocapture assays and flow cytometry to determine differential exosome levels, which predict response to therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If immune checkpoint blockade therapy is administered to all cancer patients, then more patients may potentially benefit from the therapy, but the frequency of severe toxicities and life-threatening adverse events increases
Solution Approach 1:
The patent applies preliminary action by measuring B-cell exosome levels in patient blood samples before administering immune checkpoint blockade therapy. This pre-treatment biomarker assessment identifies patients who are likely to respond to therapy while having lower risk of severe toxicities, enabling clinicians to predict treatment outcomes in advance and make informed decisions about patient eligibility.
2Object-affected harmful factors
If immune checkpoint blockade therapy is discontinued in patients with high-grade toxicities, then patient safety is improved, but treatment effectiveness is reduced due to loss of therapeutic benefit
Solution Approach 1:
By performing B-cell exosome measurement before treatment initiation, the patent enables preliminary identification of patients at low risk for high-grade toxicities. This allows clinicians to continue therapy without interruption in these patients, maintaining treatment continuity and therapeutic benefit while ensuring safety through pre-screening.
3Measurement precision
If B-cell exosome measurement is implemented to predict therapy response, then treatment personalization and effectiveness are improved, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent extracts a specific, measurable biomarker (B-cell exosomes) from the complex immune system response to cancer therapy. By focusing on this single extracellular vesicle population that can be quantified in patient blood samples, the patent simplifies the diagnostic approach while maintaining predictive accuracy, avoiding the need to analyze multiple complex immune parameters.
Solution Approach 2:
The patent changes the diagnostic parameter from complex immune system assessment to a quantifiable concentration measurement of B-cell exosomes in blood. This parameter transformation enables straightforward measurement and comparison against established thresholds, simplifying the diagnostic process while providing accurate response prediction.
Data Source
AI summary
The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. It was found that responders of immunotherapeutic treatments have a higher amount of B-cell exosomes in their blood than non-responders. Aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after B-cell exosomes have been detected in a biological sample from the subject.